Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019)